Evidence map›Paper›PMID 36441070›Full record

ArticleUrologic oncology2023

A multicenter study assessing survival in patients with metastatic renal cell carcinoma receiving immune checkpoint inhibitor therapy with and without cytoreductive nephrectomy.

Evan E Gross, Mingjia Li, Ming Yin, Delaney Orcutt, Duncan Hussey, Elliot Trott, Sarah K Holt, Erin R Dwyer, Joel Kramer, Kaylee Oliva and 17 more

Registry-linked trialOpen access · greenAbstract readMulticenter Study
PubMed Full text at PMC Publisher
In one paragraph

Article in Urologic oncology, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT07233668 (Immediate Versus Deferred Cytoreductive Nephrectomy With Ipilimumab/Nivolumab in Metastatic Clear Cell Renal Cell Carcinoma), which is not on this map. Cited by 16 papers, 2 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
16citing papers in PubMed, 2 pooled it
3.6field-weighted citation impact, top 6% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

NCT07233668 nanot yet recruitingnot on this mapstarted 2025, after this paper: background citation

Immediate Versus Deferred Cytoreductive Nephrectomy With Ipilimumab/Nivolumab in Metastatic Clear Cell Renal Cell Carcinoma: A Multicenter, Randomized, Open-Label, Phase III Trial

TypeinterventionalSponsorSeoul National University HospitalRan2025 to 2029Enrolled172ConditionsMetastatic Renal Cell Carcinoma ( mRCC)ArmsIpilimumab plus Nivolumab, Cytoreductive Nephrectomy
3 · Its place in the literature

Who cites it

16 citing papers in PubMed, 2 syntheses or guidelines pooled it, 24 citations in OpenAlex.

  1. Pooled it
  2. Pooled it
  3. Article
  4. Article
  5. Review
  6. Article
  7. Role of Cytoreductive Nephrectomy in the Immune Checkpoint Inhibitor Era: A Multicenter Collaborative Study.International journal of urology : official journal of the Japanese Urological Association · 2025
    Article
  8. Article
  9. Article
  10. Article
  11. Article
  12. The Role of Surgery in Metastatic Renal Cell Carcinoma in 2024.Clinical Medicine Insights. Oncology · 2024
    Article
  13. Article
  14. Review
  15. Review
  16. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

27 authors at 4 institutions in 1 country.

Evan E GrossThe University of Washington School of Medicine, Seattle, WA.
Mingjia LiThe Ohio State University Comprehensive Cancer Center, The James Cancer Hospital Columbus, OH.
Ming YinDivision of Medical Oncology, Department of Internal Medicine, The Ohio State University College of Medicine, Columbus, OH.
Delaney OrcuttThe University of Washington School of Medicine, Seattle, WA.
Duncan HusseyThe University of Washington School of Medicine, Seattle, WA.
Elliot TrottThe University of Washington School of Medicine, Seattle, WA.
Sarah K HoltDepartment of Urology, University of Washington, Fred Hutchinson Cancer Center, Seattle, WA.
Erin R DwyerDepartment of Urology, University of Washington, Fred Hutchinson Cancer Center, Seattle, WA.
Joel KramerThe University of Washington School of Medicine, Seattle, WA.
Kaylee OlivaThe University of Washington School of Medicine, Seattle, WA.
John L GoreDepartment of Urology, University of Washington, Fred Hutchinson Cancer Center, Seattle, WA.
George R SchadeDepartment of Urology, University of Washington, Fred Hutchinson Cancer Center, Seattle, WA.
Daniel W LinDepartment of Urology, University of Washington, Fred Hutchinson Cancer Center, Seattle, WA.
Scott S TykodiDepartment of Medicine, Division of Medical Oncology, University of Washington, Fred Hutchinson Cancer Center, Seattle, WA; Clinical Research Division, Fred Hutchinson Cancer Research Center, Seattle, WA.
Evan T HallDepartment of Medicine, Division of Medical Oncology, University of Washington, Fred Hutchinson Cancer Center, Seattle, WA; Clinical Research Division, Fred Hutchinson Cancer Research Center, Seattle, WA.
John A ThompsonDepartment of Medicine, Division of Medical Oncology, University of Washington, Fred Hutchinson Cancer Center, Seattle, WA; Clinical Research Division, Fred Hutchinson Cancer Research Center, Seattle, WA.
Anish ParikhThe Ohio State University Comprehensive Cancer Center, The James Cancer Hospital Columbus, OH.
Yuanquan YangThe Ohio State University Comprehensive Cancer Center, The James Cancer Hospital Columbus, OH.
Katharine A CollierDivision of Medical Oncology, Department of Internal Medicine, The Ohio State University College of Medicine, Columbus, OH.
Abdul MiahDivision of Medical Oncology, Department of Internal Medicine, The Ohio State University College of Medicine, Columbus, OH.
Sherry Mori-VogtDepartment of Pharmacy, The Ohio State University James Cancer Hospital and Richard J. Solove Research Institute, Columbus, OH.
Megan HinkleyDepartment of Pharmacy, The Ohio State University James Cancer Hospital and Richard J. Solove Research Institute, Columbus, OH.
Amir MortazaviDivision of Medical Oncology, Department of Internal Medicine, The Ohio State University College of Medicine, Columbus, OH.
Paul MonkThe Ohio State University Comprehensive Cancer Center, The James Cancer Hospital Columbus, OH.
Edmund FolefacDivision of Medical Oncology, Department of Internal Medicine, The Ohio State University College of Medicine, Columbus, OH.
Steven K ClintonDivision of Medical Oncology, Department of Internal Medicine, The Ohio State University College of Medicine, Columbus, OH.
Sarah P PsutkaDepartment of Urology, University of Washington, Fred Hutchinson Cancer Center, Seattle, WA. Electronic address: spsutka@uw.edu.
University of Washington · USThe Ohio State University · USFred Hutch Cancer Center · USThe Ohio State University Comprehensive Cancer Center – Arthur G. James Cancer Hospital and Richard J. Solove Research Institute · US

Funding

Training Hematology and Oncology Fellows in Clinical ResearchT32CA247815 · NCI · OHIO STATE UNIVERSITY · PI VERSCHRAEGEN, CLAIRE F., WESOLOWSKI, ROBERT · 2020 to 2024
$862k
NCI NIH HHS T32 CA247815
6 · The paper itself

Abstract

backgroundCytoreductive nephrectomy (CN) for the treatment of metastatic renal cell carcinoma (mRCC) was called into question following the publication of the CARMENA trial. While previous retrospective studies have supported CN alongside targeted therapies, there is minimal research establishing its role in conjunction with immune checkpoint inhibitor (ICI) therapy.

objectiveTo evaluate the association between CN and oncological outcomes in patients with mRCC treated with immunotherapy. MATERIALS AND

methodsA multicenter retrospective cohort study of patients diagnosed with mRCC between 2000 and 2020 who were treated at the Seattle Cancer Care Alliance and The Ohio State University and who were treated with ICI systemic therapy (ST) at any point in their disease course. Overall survival (OS) was estimated using Kaplan Meier analyses. Multivariable Cox proportional hazards models evaluated associations with mortality.

resultsThe study cohort consisted of 367 patients (CN+ST n = 232, ST alone n = 135). Among patients undergoing CN, 30 were deferred. Median survivor follow-up was 28.4 months. ICI therapy was first-line in 28.1%, second-line in 17.4%, and third or subsequent line (3L+) in 54.5% of patients. Overall, patients who underwent CN+ST had longer median OS (56.3 months IQR 50.2-79.8) compared to the ST alone group (19.1 months IQR 12.8-23.8). Multivariable analyses demonstrated a 67% reduction in risk of all-cause mortality in patients who received CN+ST vs. ST alone (P < 0.0001). Similar results were noted when first-line ICI therapy recipients were examined as a subgroup. Upfront and deferred CN did not demonstrate significant differences in OS.

conclusionsCN was independently associated with longer OS in patients with mRCC treated with ICI in any line of therapy. Our data support consideration of CN in well selected patients with mRCC undergoing treatment with ICI.

Indexed as

Carcinoma, Renal CellKidney NeoplasmsCytoreduction Surgical ProceduresHumansImmune Checkpoint InhibitorsNephrectomyRetrospective StudiesImmune Checkpoint InhibitorsCARMENACytoreductive nephrectomyImmune checkpoint inhibitorsImmunotherapyKidney cancerRenal cell carcinoma

Identifiers

PMID36441070
PMCPMC10938342
OpenAlexW4307567257

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.